ARO-DUX4

ARO-DUX4 is an investigational RNA interference (RNAi) therapeutic designed to selectively reduce the expression of the DUX4 gene in skeletal muscle. Overexpression of DUX4 is the primary cause of muscle pathology in facioscapulohumeral muscular dystrophy type 1 (FSHD1), a rare inherited disorder characterized by progressive muscle weakness, especially affecting the face, shoulders, and upper arms. By targeting and knocking down DUX4 messenger RNA transcripts, ARO-DUX4 aims to inhibit production of the toxic DUX4 protein, thereby preventing or reversing downstream myotoxicity and enabling stabilization or improvement in muscle function. Preclinical studies have shown that ARO-DUX4 can prevent and reverse disease-related changes such as body weight loss, muscle fibrosis, and functional decline in animal models. The drug is currently being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in Phase 1/2 clinical trials for FSHD1.